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Abstract
Introduction Prostate cancer (PCa) imaging is a rapidly evolving field. Dramatic improvements in prostate MRI during the 
last decade will probably change the accuracy of diagnosis. This chapter reviews recent current evidence about MRI diag-
nostic performance and impact on PCa management.
Materials and methods The International Consultation on Urological Diseases nominated a committee to review the literature 
on prostate MRI. A search of the PubMed database was conducted to identify articles focussed on MP-MRI detection and 
staging protocols, reporting and scoring systems, the role of MP-MRI in diagnosing PCa prior to biopsy, in active surveil-
lance, in focal therapy and in detecting local recurrence after treatment.
Results Differences in opinion were reported in the use of the strength of magnets [1.5 Tesla (T) vs. 3T] and coils. More 
agreement was found regarding the choice of pulse sequences; diffusion-weighted MRI (DW-MRI), dynamic contrast-
enhanced MRI (DCE MRI), and/or MR spectroscopy imaging (MRSI) are recommended in addition to conventional 
T2-weighted anatomical sequences. In 2015, the Prostate Imaging Reporting and Data System (PI-RADS version 2) was 
described to standardize image acquisition and interpretation. MP-MRI improves detection of clinically significant PCa 
(csPCa) in the repeat biopsy setting or before the confirmatory biopsy in patients considering active surveillance. It is useful 
to guide focal treatment and to detect local recurrences after treatment. Its role in biopsy-naive patients or during the course 
of active surveillance remains debated.
Conclusion MP-MRI is increasingly used to improve detection of csPCa and for the selection of a suitable therapeutic 
approach.
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Introduction
Over the past few years, many independent groups from all 
over the world have reported excellent results in the detec-
tion of clinically significant prostate cancer (csPCa) using 
multi-parametric Magnetic Resonance Imaging (MP-MRI). 
As a result, MP-MRI has become highly integrated into the 
diagnostic workup of patients at risk for prostate cancer (PCa). 
However, despite its growing use, MP-MRI is not always per-
formed in a uniform manner and it is important that standard-
ized imaging guidelines be produced so that patients get the 
best diagnostic value from the examination they undergo [1]. 
This article presents current guidelines for imaging acquisi-
tion, reporting and scoring, and MP-MRI results in PCa detec-
tion and staging. Finally, it reviews the potential role of MP-
MRI in the management of clinically localised PCa.
Methodology
A committee was nominated by the ICUD to review the cur-
rent literature covering the role of MP-MRI in localised PCa 
management. A literature search was performed through 
PubMed database which focussed on the following topics: 
MP-MRI detection and staging protocols, reporting and scor-
ing systems, the role of MP-MRI in diagnosing PCa prior to 
biopsy, in active surveillance, in focal therapy and in detecting 
local recurrence after treatment. The results of this analysis 
were first presented during a joint international consultation 
of the ICUD and the Société Internationale d’Urologie (SIU) 
held in Melbourne (Australia) on October 2015. The PubMed 
search was updated to add most recent publications.
Review
In an effort to harmonize practices, several professional societies 
have published guidelines describing how to perform, interpret 
and report prostate MP-MRI [2, 3]. Those guidelines include 
technical recommendations on how to perform the examination 
properly, how to localize and describe a suspicious image on 
all MRI sequences using unified terminology and how to sum-
marize its likelihood of malignancy on a standardized five-point 
scale. They also describe how to communicate these findings to 
the requesting physician in a satisfactory manner.
Optimizing imaging protocols for localised 
prostate cancer
Detection protocol
For PCa detection, MP-MRI can be obtained at 1.5 Tesla 
(T) or 3T, using either a combination of an endorectal coil 
(ERC) and a pelvic phased-array coil, or a pelvic phased-
array coil only. The use of an ERC and/or examination at 
high field strength (3T) provides higher signal-to-noise 
ratio, and this extra signal can be used to improve resolu-
tion, speed of acquisition and/or diffusion imaging [4]. 
Nonetheless, good results for PCa detection have been 
published at 1.5T without using an ERC. The use of ERC 
and 3T imaging is, therefore, optional. Imaging at low 
field strength (< 1.5T) is discouraged [3].
The imaging protocol should include at least T2-weighted 
(T2W), diffusion-weighted (DW) and dynamic contrast-
enhanced (DCE). T2W imaging should include images acquired 
along the axial, coronal and sagittal planes. DW imaging should 
be obtained along the axial plane and include at least three b 
values with reconstruction of an Apparent Diffusion Coeffi-
cient (ADC) map (Fig. 1). It is essential to obtain a maximal b 
value ≥ 1400 s/mm2. DCE imaging should be acquired along 
the axial plane, with a temporal resolution ≤ 15 s and prefer-
ably ≤ 7 s. MR spectroscopy imaging (MRSI) is currently con-
sidered optional and has been relegated to the research setting.
One important challenge with DW imaging when an 
ERC is not used is the presence of rectal gas that may 
generate susceptibility and distortion artefacts, which can 
potentially limit lesion detection. A proper preparation of 
patient, including inserting small intrarectal tubes to expel 
rectal gas is fundamental.
When MP-MRI is obtained after prostate biopsy, a delay 
of at least 6–8 weeks must be observed to minimize the 
risk of bleeding artefacts. Haemorrhage is indeed respon-
sible for hyperintense signal on T1-weighted (T1  W) 
images and hypointense signal on T2W images that may 
mimic prostate cancer and decrease MP-MRI positive pre-
dictive value. Axial T1-weighted images may be added to 
the imaging protocol to detect residual bleeding artefacts 
when MP-MRI is performed after biopsy.
Staging protocol
The purpose of local staging is to detect extra-capsular 
extension (ECE; T3a disease) and seminal vesicle invasion 
(SVI; T3b disease). Currently, MP-MRI is the most prom-
ising method for local staging prior to treatment although 
it has limitations in sensitivity.
The main features used to assess ECE are either overt/
direct findings (direct extension visible in the periprostatic 
fat, obliteration of the rectoprostatic angle) or secondary 
features (capsular bulge, irregularity, broad capsular con-
tact with the tumour, etc.) that are strongly associated with 
ECE. Features of SVI include focal low-signal intensity on 
T2W images and/or focal enhancement on DCE imaging.
The evaluation of the prostatic capsular invasion requires 
very high spatial resolution and high image quality. Better 
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spatial resolution can be achieved with combined use of 
ERC and a pelvic phased-array coil at 3T [5]. However, 
Park et al. [6] reported that MP-MRI with an ERC at 1.5T 
had comparable accuracy in local staging compared to no 
ERC MP-MRI at 3T (70 vs. 72% for with ERC vs. no ERC 
protocols, respectively). On the other hand, the use of the 
ERC significantly increased staging performance, and sen-
sitivity for detection of locally advanced disease by expe-
rienced readers was increased from 7% (1 of 15) to a range 
of 73% (11 of 15) to 80% (12 of 15) (p < 0.05), whereas a 
high specificity of 97% (30 of 31) to 100% (31 of 31) was 
maintained [7]. SVI is less sensitive to the need for an ERC 
and can be detected with either ERC or non-ERC MP-MRI 
protocols especially if the SVs are well distended.
Critical pulse sequences for optimizing a staging MP-
MRI protocol include axial T1 W imaging (for depiction of 
biopsy-related haemorrhage), tri-plane T2W imaging, DW 
imaging and DCE imaging. This multi-parametric approach 
not only enables staging, but also aids in predicting the 
aggressiveness of the lesions [8]. Moreover, DCE imaging 
is useful for SVI as enhancement of a seminal vesicle mass 
is highly suggestive of invasion [9]. Staging ability of MRSI 
is limited by the requirement of a large voxel size [10].
MRI reporting and scoring
The first step of the interpretation process is to detect suspi-
cious lesions within the gland. Reading has to be performed 
methodically and should independently assess each of the 
three main compartments of the gland: the peripheral zone 
(PZ), the transition zone (TZ), and the anterior fibromuscu-
lar stroma (AFMS), because diagnosis of csPCa relies on 
different criteria in these three zones [11]. Such analysis 
allows faster review of the entire gland, without omission. 
This task is easier when the multi-parametric protocol is 
respected because DCE imaging allows quick detection of 
foci of increased vascularization that usually matches with 
cancer in the peripheral zone, or foci of cancer difficult to 
detect on T2W or DW imaging.
Because there is a large overlap between appearances of 
PCa and benign findings at MP-MRI, each visible lesion 
must receive a five-level score of likelihood of malignancy, 
ranging from the lowest (1/5) to the highest (5/5) degree of 
suspicion for malignancy [2].
Initial guidelines recommended an entirely subjective 
scoring that was based only on the radiologist experience 
(so-called Likert score) [12]. A score of 1/5, depicting com-
pletely normal peripheral (bright and homogeneous on T2W 
images, without restriction or enhancement) or transition 
zone tissue, has a high likelihood of being benign, whereas 
on the contrary, a score of 5/5, depicting a typical cancer (PZ 
nodule with marked low-signal intensity on T2W images, 
marked restriction of diffusion and early enhancement), has 
the highest likelihood of corresponding to a csPCa. In prac-
tice, many benign areas of tissue show some abnormalities 
(scars and abnormal enhancement) accounting for the major-
ity of scores of 2/5. The majority of csPCa show discordant 
findings on different pulse sequences, with either atypical 
DW or DCE imaging findings, or non-nodular appearance, 
accounting for the majority of scores of 4/5. Remaining 
lesions (scoring of 3/5, “equivocal”) show moderate signal 
Fig. 1  63-year-old man with a PSA = 4.7  ng/ml. Multi-parametric 
MRI obtained with combined use of an endorectal coil including 
axial T2W MRI (a), ADC map of DW-MRI (b), b2000 s/mm2 DW-
MRI (c) and DCE MRI (d) shows a lesion in the left mid-peripheral 
zone (arrows). The same patient underwent a multi-parametric MRI 
with 32-channel-phased-array surface coil a year after the initial MP-
MRI, which again localizes the same lesion on axial T2W MRI (e), 
ADC map of DW-MRI (f), b1500 s/mm2 DW-MRI (g), DCE MRI (h) 
(arrows). The lesion was biopsied via TRUS/MRI fusion guidance 
and found to include Gleason 3 + 3 prostate cancer
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changes and/or atypical morphology, and can either be 
malignant or benign.
In an effort to harmonize practices, the European Soci-
ety of Uro-Radiology (ESUR) published professional rec-
ommendations in 2012 and introduced the Prostate Imag-
ing Reporting and Data System version 1 (PI-RADS v1)2. 
This scoring system described five-level scores for T2W, 
DW and DCE imaging, and for MRSI. However, it did not 
clearly define if the “final” PI-RADS score of a suspicious 
image had to be a sum of the three or four individual scores 
(ranging from 3 to 15 or 4 to 20), an average score (ranging 
from 1 to 5), or just a decision support to let the radiologist 
allocate the definitive score subjectively, with knowledge 
of additional criteria the PI-RADS system did not take into 
account (clinical information, lesion size, etc.).
An updated version of the PI-RADS scoring system (PI-
RADS v2) has been published in 2016 [3]. It clarifies how 
to assign an individual score to the different pulse sequences 
(T2W, DW and DCE imaging), how to describe the findings 
using a glossary of terms, and finally, how to build the final 
five-point-scaled PI-RADS v2 score of the lesion, using a 
detailed scoring algorithm (Tables 1 and 2).
PI-RADS v2 is specifically aimed at providing a likeli-
hood of malignancy for clinically significant cancer (defined 
as Gleason score ≥ 7 and/or volume ≥ 0.5 cc and/or extrapro-
static extension). It introduces the concept of a “dominant” 
sequence depending on the location of the image in the 
gland. DW imaging is thus the dominant sequence for PZ 
lesions, with a minor contribution of DCE imaging. InTZ, 
T2W imaging is the dominant sequence, with a minor con-
tribution of DW imaging. Thus, T2W imaging has no influ-
ence on the score in PZ, and DCE has no influence on the 
score in TZ.
This new version states that PI-RADS score assessment 
should be strictly based on objective MP-MRI findings, and 
not incorporate factors such as the PSA, DRE, or other clini-
cal information.
Several studies have demonstrated good performance of 
the PI-RADS v1 score for the classification of suspicious 
lesions, and moderate-to-good inter-reader agreement 
between readers. In a prospective two-center study that 
included 118 patients, Renard-Penna et al. [13] showed in 
2015 that a summed PI-RADS v1 score of 9/15 or greater, 
achieved a sensitivity and a specificity of 86.6 and 82.4%. 
Sensitivity and specificity of a subjective Likert scale score 
of 3/5 or greater were 93.8 and 73.6%, respectively. In 
another series of 215 patients, Vaché et al. [14] observed 
respective areas under the ROC curve (AUC) of 0.80 and 
0.74 in PZ for subjective Likert scoring and objective PI-
RADS v1 scoring, respectively. In TZ, the AUC were 0.87 
vs. 0.82, respectively, with statistically significant differ-
ences in both cases. Other studies also suggest that PI-RADS 
v1 criteria did not completely reflect all the components of Ta
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an expert’s judgement, or did not include significant criteria 
described in other scoring systems (e.g. size of the lesion, 
anterior or inferior location of TZ cancers, posterolateral 
location of PZ cancers, specific AFMS cancers, etc.).
The recent introduction of the PI-RADS v2 score did 
improve the accuracy of the scoring, with an increased sensi-
tivity and a similar specificity, as compared to the PI-RADS 
v1 score [15].
MP‑MRI and prostate biopsy
Pre-biopsy MP-MRI aids in prostate cancer identification, 
localization, characterization of aggressiveness, estima-
tion of volume and contour. Furthermore, biopsy targeting 
lesions seen on MP-MRI improves the diagnostic yield of 
clinically significant (cs) PCa detection rate and reduces 
the number of insignificant PCa diagnosed in patients [16]. 
Another advantage of pre-Bx MRI is that it avoids post-
biopsy bleeding artefacts that restrain accuracy for PCa 
detection.
Franiel et al. [17] investigated whether MP-MRI was 
helpful in differentiating low-grade (Gleason score ≤ 6) and 
high-grade (Gleason score > 7) PCa. Using DCE kinetic 
models, low-grade PCa had significantly higher mean blood 
volume (1.76 vs. 1.64%, p = 0.039), longer mean transit time 
(6.39 vs. 3.25 s, p < 0.001), and lower mean permeability 
(2.57 vs. 3.86 min (− 1), p = 0.011) than high-grade PCa. 
These features, achieved using 1.5-T MP-MRI, could be used 
to properly assess tumour aggressiveness and better manage 
the patient.
Pre-biopsy MP-MRI may improve csPCa detection by 
directly targeting suspicious areas during the subsequent 
biopsy procedure. In the systematic review by Moore et al. 
[18], PCa was detected in 30% of targeted cores (375 out 
of 1252) versus 7% of systematic cores (368 out of 5441). 
On a per patient basis, the cancer detection rate was 36% 
(526 of 1442) for standard biopsy and 48% (650 of 1345) 
for targeted biopsy. A meta-analysis by Schoots et al. [19] 
including 16 studies did not find any significant difference 
in the overall PCa detection by systematic and targeted 
biopsy [sensitivity of 0.81 (95% confidence interval (CI) 
0.70–0.88) versus 0.85 (95% CI 0.80–0.89)]. Targeted 
and systematic biopsy missed the diagnosis of prostate 
cancer in 15 and 19% of cases, respectively. However, tar-
geted biopsy had a higher detection rate for csPCa [sen-
sitivity of 0.91 (95% CI 0.87–0.94) versus 0.76 (95% CI 
0.64–0.84)] and a lower detection rate of insignificant 
PCa [sensitivity of 0.44 (95% CI 0.26–0.64) versus 0.83 
(95% CI 0.77–0.87)]. Therefore, targeted biopsy may not 
only improve the detection of csPCa. It may also dimin-
ish subsequent overtreatment by reducing the detection of 
indolent PCa (over diagnosis). This was further confirmed 
by a randomized trial recently published by Panebianco 
et al. [20].
It is of note, however, that in the meta-analysis by Schoots 
et al. [19],the increased detection of csPCa due to targeted 
biopsy was significant only in the repeat biopsy setting. In 
patients with history of negative prior biopsy, the relative 
sensitivity between targeted and systematic biopsy was 1.54 
(95% CI 1.05–2.57). It was only 1.10 (95% CI 1.00–1.22) 
in biopsy-naive patients. This can be explained by the fact 
that the repeat biopsy group is more favourable for target 
biopsy, with an increased prevalence of anterior tumours 
that are well detected by MP-MRI, but tend to be missed by 
systematic biopsy.
Whether pre-biopsy MP-MRI can improve csPCa detec-
tion in biopsy-naive patients remains unclear. A recent 
randomized trial performed by Baco et al. compared two 
methods (12-core random biopsy versus 2-core MRI-tar-
geted biopsy plus 12-core random biopsy) and reported no 
difference between those for diagnosing csPCa (defined as 
maximum cancer length ≥ 5 mm in Gleason 6 cancers or any 
Gleason ≥ 7 cancer) [21].
The role of MP‑MRI in active surveillance
The literature on the role of MP-MRI in patients consider-
ing active surveillance (AS) or already enrolled in an AS 
program is scarce. Because it has a high sensitivity for 
csPCa, MP-MRI could assist in the appropriate selection of 
Table 2  Semiology criteria used for scoring peripheral (PZ) and transition (TZ) zone lesions on the dynamic contrast-enhanced, T1-weighted 
series (DCE) in the 2015 PI-RADS v2 scoring system
Note that series score is not ranging from 1 to 5 like in other sequences, but only “positive” or “negative”
Series score PZ or TZ
DCE
Negative (−) No early enhancement, or diffuse enhancement not corresponding to a focal finding on 
T2W and/or DW imaging or focal enhancement corresponding to a lesion demonstrating 
features of BPH on T2W imaging
Positive (+) Focal, and earlier than or contemporaneously with enhancement of adjacent
normal prostatic tissues, and; corresponds to suspicious finding on T2W and/or DW imaging
434 World Journal of Urology (2019) 37:429–436
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patients for AS [22]. Its role during the follow-up period of 
AS remains unclear. Particularly, it is still unclear whether a 
negative MP-MRI could obviate the need for prostate biopsy 
in patients under AS. The ideal frequency of MP-MRI fol-
low-up is already unknown.
The role of MP‑MRI in focal therapy
Determining prostate cancer volume and contours is of 
paramount importance for targeting focal therapy. Thus far, 
some studies evaluated tumour volume estimation at MP-
MRI. Tumour volume tends to be underestimated by all MP-
MRI pulse sequences [23, 24]. Thus, it is advised to destroy 
a much larger region of the gland than the one indicated 
by MP-MRI in to allow full tumour destruction. It seems 
that this discrepancy in boundary may be most significant 
at the non-capsular side of the lesion given the tendency for 
tumours to originate close to the capsule and exhibit cen-
tripetal growth within the gland [25]. These findings have 
a key implication in planning and performing focal therapy 
procedures and would suggest the respect of a security mar-
gin to be confident of full tumour destruction in view of the 
larger histologic volume [26].
During treatment, MP-MRI provides two key advantages 
for an effective focal ablation over other imaging modali-
ties. First, its excellent soft tissue contrast and multi-planar 
imaging capabilities allow for clear visualization and locali-
zation of the tumour and for accurate probe placement into 
the lesion. Second, if the procedure is performed under MR 
guidance, MR thermometry can be used to non-invasively 
monitor and control the ablation in real time by measur-
ing the spatial distribution of tissue temperature during the 
thermal ablation. Finally, MRI can also be used to assess 
the ablation size and validate the completeness of the focal 
therapy covering the target lesion [27].
In thermal ablation, tissue heating induces coagula-
tive necrosis in the target area, which becomes completely 
devascularized and surrounded by inflammation and edema 
[28]. MR images within days after high-intensity focussed 
ultrasound may show a significant increase of the prostate 
volume, presumably due to transient edema, with slightly 
hyperintense areas on T1-weighted images, most likely rep-
resenting interstitial haemorrhage, and a central hypointense 
and ill-defined lesion on T2-weighted images. Similar find-
ings are seen after photodynamic therapy, T2 heterogeneous 
signals are seen that are related to the edema and ischemic 
modifications induced by phototherapy.
After 3–5 months, the prostate shrinks and the paren-
chyma becomes diffusely hypointense and ill-defined, with 
loss of the normal zonal anatomy on T2-weighted images. 
This MRI appearance of HIFU and laser ablation-induced 
changes is identical to those associated with cryotherapy 
(which induces cell death by hypothermic coagulation 
necrosis, direct cellular toxicity due to disruption of the 
cell membrane by formation of “ice ball crystals” and gene 
regulated cell death) [29]. At 6 months after photodynamic 
therapy, important changes of the prostate shape and signal 
are found [30]. Small areas of residual necrosis may still 
be present in the treated lobe, corresponding to coagulation 
necrosis.
The role of MP‑MRI in detecting local 
recurrences after treatment
The goal of imaging in biochemical relapse after treatment 
is to detect local and/or metastatic recurrence. Technical 
improvements of prostatic MRI allow early detection of 
local recurrence after radical treatments (radical prostatec-
tomy and radiation therapy) or focal therapy (high-intensity 
focussed ultrasound (HIFU), cryosurgery, and photodynamic 
therapy).
The most common site of postoperative local recurrence 
after radical prostatectomy is the urethrovesical anastomo-
sis around the bladder neck and the membranous urethra 
(40–55%) [31]. MP-MRI can discriminate local relapse from 
residual glandular healthy tissue, scar/fibrosis, and granula-
tion tissue. The presence, on T2W images, of a lobulated 
nodular-like or mass-like soft tissue thickening in the pros-
tatectomy bed that appears slightly hyperintense compared 
to pelvic muscles should be considered to be strongly sug-
gestive of local recurrence.
Recurrent tumours tend to enhance faster and more avidly 
after gadolinium administration in the early arterial phase, 
followed by a plateau or washout during the venous phase, 
while postoperative fibrosis tends to show either no enhance-
ment or mild enhancement in the venous phase [32]. DCE 
imaging has been reported to increase diagnostic sensitivity 
from 48 to 88% and specificity from 52 to 100% compared 
with T2W MRI alone, and allows the detection of recurrent 
tumours measuring more than 5 mm, for a PSA level of less 
than 2 ng/mL, with a negative predictive value of 95% [33]. 
As a result, DCE imaging can be considered as the most 
reliable MRI technique for the detection of local prostate 
cancer recurrence after RP.
After external radiation beam radiotherapy (EBRT), the 
prostate appears decreased in volume, diffusely hypointense 
on T2 W images, with a loss of zonal anatomy. The seminal 
vesicles also appear globally hypointense.
Recurrences are most commonly located in the origi-
nal tumour site [34]. T2W imaging alone is of a limited 
diagnostic accuracy because the recurrent tumour and the 
normal surrounding parenchyma both appear hypointense 
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[35]. Cancer can be detected under such circumstances if its 
signal intensity is lower than adjacent prostate tissue, and 
if it appears nodular or with a mass-like effect. Recurrent 
tissue appears as hypervascular early enhancing homogene-
ous nodule, with an early washout, whereas in fibrosis the 
enhancement is homogeneous, slow, and less intense. So, 
the combination of T2W and DW-MRI appears to be the 
optimal approach.
Brachytherapy induces a decrease in volume of the pros-
tate gland and seminal vesicles, as does EBRT. The prostate 
gland appears globally hypointense on T2W images, with 
loss of zonal anatomy. The capsule appears irregular, and the 
seminal vesicle appears hypointense on T2 weighted images 
as well. Brachytherapy seeds can be seen on all sequences 
but more particularly during DCE imaging. However, sensi-
tivity of DW imaging in detecting recurrent tumour was sig-
nificantly higher than that of T2W MRI. MP-MRI achieved 
the highest sensitivity (77%), but with slightly decreased 
specificity (92%) [36].
After HIFU, MP-MRI is recommended to detect recur-
rence at 6 months follow-up. However, prostatic paren-
chyma is heterogeneously and diffusely hypointense on T2W 
images with a loss of normal zonal anatomy, which makes it 
difficult to analyze [37]. Therefore, it is essential to combine 
T2W MRI with DCE MRI and DW-MRI to differentiate 
residual/recurrent cancers (which are usually hypervascular) 
from post-HIFU fibrosis (which is rather homogeneous and 
hypovascular).
After cryotherapy, DCE imaging, DW imaging, and 
MRSI allow for the detection of recurrence in the same way 
as for HIFU ablation [38].
Conclusion
A large body of the literature suggests that MP-MRI has 
become a reliable tool for assessing the presence and size of 
aggressive cancer in the prostate. By improving the detec-
tion of significant prostate cancer, MP-MRI could be used 
for the selection of a suitable therapeutic approach and its 
evaluation. Recent initiatives have been made by the interna-
tional radiological community to define a standardized way 
to interpret MR images. This raises the hope that the good 
results obtained with prostate MP-MRI by specialized aca-
demic groups will be soon reproduced in less-experienced 
centers.
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